Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GenSci 120

Next Previous
Drug Profile

GenSci 120

Alternative Names: GenSci-120

Latest Information Update: 08 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeneScience Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Immunotherapies; Irritable bowel syndrome therapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders; Inflammatory bowel diseases; Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 06 Jun 2026 Pharmacokinetic, adverse event and pharmacodynamic data from phase I trial in Autoimmune disorders presented at 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)
  • 30 Apr 2026 Phase-II clinical trials in Rheumatoid arthritis (Treatment-resistant) in China (SC) (NCT07423533)
  • 27 Mar 2026 Phase-I clinical trials in Systemic lupus erythematosus, Sjogren's syndrome, Rheumatoid arthritis, Inflammatory bowel diseases (SC) (GeneScience Pharmaceuticals pipeline, March 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top